As far as coronavirus vaccine plays are concerned, Modern (NASDAQ:MRNA) has been one of the clear winners. The company is on course to perform solidly in 2021 and is on track to deliver 800 million to 1 million shots in total this year.
That is going to work out to sales of $19 billion and that is a massive jump from the revenues of less than $1 billion in 2019. In addition to that, the COVID 19 vaccine has also proven to be massively profitable. In Q1 2021, Moderna generated a net profit margin of 70% in the vaccine.
Experts believe that the company is going to benefit from its vaccine sales in 2022 as well and it is expected to be the prime driver of growth. In this regard, it is necessary to note that the vaccination drive at a global level is still at its early stages. Only 10% of the global population have been fully vaccinated so far and hence, Modern could end up driving considerable growth in 2022 as well.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.